Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia

被引:36
作者
Miller, Christopher C. [1 ,2 ]
Hergott, Christopher A. [3 ,4 ]
Rohan, Marta [3 ,4 ]
Arsenault-Mehta, Kyle [3 ,4 ]
Doering, Gerd [5 ]
Mehta, Sanjay [3 ,4 ]
机构
[1] Univ British Columbia, Div Resp Med, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, Div Infect Dis, Vancouver, BC V5Z 1M9, Canada
[3] Lawson Hlth Res Inst, Ctr Crit Illness Res, London Hlth Sci Ctr, Dept Med,Resp Div, London, ON, Canada
[4] Western Univ, Schulich Sch Med & Dent, Dept Med, London, ON, Canada
[5] Univ Klinikum Tubingen, Inst Med Microbiol & Hyg, Tubingen, Germany
关键词
Cystic fibrosis; Nitric oxide; Inhalation; P. aeruginosa pneumonia; Myeloperoxidase; CYSTIC-FIBROSIS; ANTIMICROBIAL ACTIVITY; INFECTION; INJURY; ADULTS;
D O I
10.1016/j.jcf.2013.01.008
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Gaseous nitric oxide (NO) is bactericidal in vitro. However whether and how it can be used for the treatment of bacterial lung infections in patients with cystic fibrosis is unclear. Here we assessed the bactericidal effect of intermittently inhaled 160 ppm NO for 30 min every 4 h in a Pseudomonas aeruginosa pneumonia model in rats. NO significantly reduced P. aeruginosa colony count in rat lungs but did not affect neutrophil myeloperoxidase function methemoglobin percentage nor plasma nitrite/nitrate levels. This regimen warrants exploration in infected patients with cystic fibrosis. (C) 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:817 / 820
页数:4
相关论文
共 19 条
[1]   Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)-A cause for concern? [J].
Ashish, Abdul ;
Shaw, Matthew ;
Winstanley, C. ;
Ledson, Martin J. ;
Walshaw, Martin J. .
JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (03) :173-179
[2]   Effects of nitric oxide on Pseudomonas aeruginosa infection of epithelial cells from a human respiratory cell line derived from a patient with cystic fibrosis [J].
Darling, KEA ;
Evans, TJ .
INFECTION AND IMMUNITY, 2003, 71 (05) :2341-2349
[3]   Treatment of lung infection in patients with cystic fibrosis: Current and future strategies [J].
Doering, Gerd ;
Flume, Patrick ;
Heijerman, Harry ;
Elborn, J. Stuart ;
Angyalosi, G. ;
Assael, B. ;
Bell, S. ;
Bilton, D. ;
De Boeck, K. ;
Bush, A. ;
Campbell, P. W., III ;
Cattaneo, A. ;
Dembowsky, K. ;
Drevinek, P. ;
Dubois, C. ;
Eichler, I. ;
Elborn, J. S. ;
Flume, P. A. ;
Foweraker, J. E. ;
Gallagher, C. ;
Gartner, S. ;
Geller, D. E. ;
Goldman, M. ;
Goss, C. H. ;
Gupta, R. ;
Heijerman, H. G. ;
Henig, N. ;
Higgins, M. ;
Hjelte, L. ;
Hoiby, N. ;
Jongejan, R. ;
Knoch, M. ;
Konstan, M. W. ;
Muhlebach, M. S. ;
Nieuwenhuizen, P. W. ;
Parkins, M. D. ;
Pressler, T. ;
Quittner, A. L. ;
Ratjen, F. ;
Ramsey, B. W. ;
Smyth, A. ;
Thieroff-Ekerdt, R. ;
Tullis, E. ;
van der Ent, C. K. ;
Vazquez, C. ;
Wainwright, C. E. .
JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (06) :461-479
[4]   Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease [J].
Doering, Gerd ;
Gulbins, Erich .
CELLULAR MICROBIOLOGY, 2009, 11 (02) :208-216
[5]   Mechanisms of nitric oxide-related antimicrobial activity [J].
Fang, FC .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (12) :2818-2825
[6]  
Food and Drug Administration, 1999, APPR NDA 20 846 INOM
[7]   Potential application of gaseous nitric oxide as a topical antimicrobial agent [J].
Ghaffari, A ;
Miller, CC ;
McMullin, B ;
Ghahary, A .
NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2006, 14 (01) :21-29
[8]   Drug therapy - Inhaled nitric oxide therapy in adults [J].
Griffiths, MJD ;
Evans, TW .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (25) :2683-2695
[9]  
McMullin Bevin B, 2005, Respir Care, V50, P1451
[10]   A phase I clinical study of inhaled nitric oxide in healthy adults [J].
Miller, Chris ;
Miller, Minna ;
McMullin, Bevin ;
Regev, Gilly ;
Serghides, Lena ;
Kain, Kevin ;
Road, Jeremy ;
Av-Gay, Yossef .
JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (04) :324-331